Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

30.46
-1.6300-5.08%
Post-market: 30.460.00000.00%16:34 EDT
Volume:693.96K
Turnover:21.38M
Market Cap:2.67B
PE:-23.71
High:32.05
Open:31.90
Low:30.36
Close:32.09
52wk High:39.28
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:0.49
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2849
EPS(LYR):-1.2849
ROE:-10.92%
ROA:-8.92%
PB:2.61
PE(LYR):-23.71

Loading ...

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Oct 31, 2025

Press Release: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Oct 31, 2025

UBS Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Oct 25, 2025

IDEAYA Biosciences: Strong Clinical Data and Financial Position Justify Buy Rating

TIPRANKS
·
Oct 24, 2025

IDEAYA Biosciences Is Maintained at Overweight by JP Morgan

Dow Jones
·
Oct 24, 2025

U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic

Reuters
·
Oct 23, 2025

Mizuho Securities Remains a Buy on IDEAYA Biosciences (IDYA)

TIPRANKS
·
Oct 22, 2025

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA) and Rani Therapeutics Holdings (RANI)

TIPRANKS
·
Oct 21, 2025

RBC Raises Price Target on IDEAYA Biosciences to $41 From $38, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Oct 21, 2025

IDEAYA Biosciences Price Target Maintained With a $62.00/Share by BTIG

Dow Jones
·
Oct 21, 2025

Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)

TIPRANKS
·
Oct 21, 2025

U.S. RESEARCH ROUNDUP-Block, Morgan Stanley, W R Berkley

Reuters
·
Oct 21, 2025

Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials

TIPRANKS
·
Oct 21, 2025

IDEAYA Biosciences Presents Promising Phase 2 Data

TIPRANKS
·
Oct 21, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Arm Holdings, silver miners, Zions Bancorp

Reuters
·
Oct 21, 2025

IDEAYA Biosciences Shares Rise 2.3% After Co's Drug Combo Shows Survival Benefit in Rare Eye Cancer Trial

THOMSON REUTERS
·
Oct 20, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Planet Labs, WW International

Reuters
·
Oct 20, 2025

BUZZ-Ideaya rises as drug combo shows survival benefit in rare eye cancer trial

Reuters
·
Oct 20, 2025

Ideaya Biosciences presents clinical data from OptimUM-09 trial

TIPRANKS
·
Oct 20, 2025

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at Esmo 2025

THOMSON REUTERS
·
Oct 20, 2025